Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange Detected- Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.SummaryDifference11%
- Check14 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.3%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed, a minor UI change with no impact on core content or functionality.SummaryDifference0.7%
- Check36 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%
- Check43 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This indicates a shift towards a more generalized presentation of location data.SummaryDifference25%
- Check58 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.